Effects of (-)-Epicatechin on Myocardial Infarct Size and Left Ventricular Remodeling After Permanent Coronary Occlusion

Journal of the American College of Cardiology

Volumn 55, Issue 25, 2010, Pages 2869-2876

  Yamazaki, Katrina Go ^a   Taub, Pam R ^a   Barraza Hidalgo, Maraliz ^a   Rivas, Maria M ^a   Zambon, Alexander C ^a   Ceballos, Guillermo ^b   Villarreal, Francisco J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

Author keywords

cardioprotection; catechins; flavanols; infarction; ischemia

Indexed keywords

EPICATECHIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; ENZYME ACTIVATION; FUNCTIONAL ASSESSMENT; HEART INFARCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE MASS; HEART LEFT VENTRICLE PRESSURE; HEART PROTECTION; HEART RATE VARIABILITY; HEART WEIGHT; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; RAT; SHAM PROCEDURE; SIGNAL TRANSDUCTION; THICKNESS; THORACOTOMY; TISSUE STRUCTURE; WESTERN BLOTTING;

ADMINISTRATION, ORAL; ANALYSIS OF VARIANCE; ANIMALS; CATECHIN; CORONARY CIRCULATION; CORONARY OCCLUSION; DISEASE MODELS, ANIMAL; HEMODYNAMICS; MALE; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; PROBABILITY; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; REFERENCE VALUES; SURVIVAL RATE; TREATMENT OUTCOME; VENTRICULAR REMODELING;

EID: 77953308194     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2010.01.055     Document Type: Article

References (46)

1. Middleton Jr. E. Effect of plant flavonoids on immune and inflammatory cell function. Adv Exp Med Biol 439 (1998) 175-182
2. Keen C.L., Holt R.R., Oteiza P.I., Fraga C.G., and Schmitz H.H. Cocoa antioxidants and cardiovascular health. Am J Clin Nutr 81 (2005) 298S-303S
3. Kris-Etherton P.M., and Keen C.L. Evidence that the antioxidant flavonoids in tea and cocoa are beneficial for cardiovascular health. Curr Opin Lipidol 13 (2002) 41-49
4. Knekt P., Jarvinen R., Reunanen A., and Maatela J. Flavonoid intake and coronary mortality in Finland: a cohort study. Bmj 312 (1996) 478-481
5. Hertog M.G., Kromhout D., Aravanis C., et al. Flavonoid intake and long-term risk of coronary heart disease and cancer in the seven countries study. Arch Intern Med 155 (1995) 381-386
6. Fisher N.D., and Hollenberg N.K. Flavanols for cardiovascular health: the science behind the sweetness. J Hypertens 23 (2005) 1453-1459
7. McCullough M.L., Chevaux K., Jackson L., et al. Hypertension, the Kuna, and the epidemiology of flavanols. J Cardiovasc Pharmacol 47 Suppl 2 (2006) S103-S109 discussion 119-21
8. Hollenberg N.K., Martinez G., McCullough M., et al. Aging, acculturation, salt intake, and hypertension in the Kuna of Panama. Hypertension 29 (1997) 171-176
9. Janszky I., Mukamal K.J., Ljung R., Ahnve S., Ahlbom A., and Hallqvist J. Chocolate consumption and mortality following a firstacute myocardial infarction: the Stockholm Heart Epidemiology Program. J Int Med 266 (2009) 248-257
10. Heiss C., Dejam A., Kleinbongard P., Schewe T., Sies H., and Kelm M. Vascular effects of cocoa rich in flavan-3-ols. JAMA 290 (2003) 1030-1031
11. Fisher N.D., Hughes M., Gerhard-Herman M., and Hollenberg N.K. Flavanol-rich cocoa induces nitric-oxide-dependent vasodilation in healthy humans. J Hypertens 21 (2003) 2281-2286
12. Nijveldt R.J., van Nood E., van Hoorn D.E., Boelens P.G., van Norren K., and van Leeuwen P.A. Flavonoids: a review of probable mechanisms of action and potential applications. Am J Clin Nutr 74 (2001) 418-425
13. Corti R., Flammer A.J., Hollenberg N.K., and Luscher T.F. Cocoa and cardiovascular health. Circulation 119 (2009) 1433-1441
14. Yamazaki K.G., Romero-Perez D., Barraza-Hidalgo M., et al. Short- and long-term effects of (-)-epicatechin on myocardial ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol 295 (2008) H761-H767
15. Hausenloy D.J., and Yellon D.M. Reperfusion injury salvage kinase signalling: taking a RISK for cardioprotection. Heart Fail Rev 12 (2007) 217-234
16. Hausenloy D.J., Tsang A., Mocanu M.M., and Yellon D.M. Ischemic preconditioning protects by activating prosurvival kinases at reperfusion. Am J Physiol Heart Circ Physiol 288 (2005) H971-H976
17. Garcia R.A., Go K.V., and Villarreal F.J. Effects of timed administration of doxycycline or methylprednisolone on post-myocardial infarction inflammation and left ventricular remodeling in the rat heart. Mol Cell Biochem 300 (2007) 159-169
18. Kingma Jr. J.G., and Yellon D.M. Limitation of myocardial necrosis with verapamil during sustained coronary occlusion in the closed-chest dog. Cardiovasc Drugs Ther 2 (1988) 313-323
19. Smith III E.F., Egan J.W., and Griswold D.E. Effect of propranolol on ischemic myocardial damage and left ventricular hypertrophy following permanent coronary artery occlusion or occlusion followed by reperfusion. Pharmacology 38 (1989) 298-309
20. Kaga S., Zhan L., Matsumoto M., and Maulik N. Resveratrol enhances neovascularization in the infarcted rat myocardium through the induction of thioredoxin-1, heme oxygenase-1 and vascular endothelial growth factor. J Mol Cell Cardiol 39 (2005) 813-822
21. Gundewar S., Calvert J.W., Jha S., et al. Activation of AMP-activated protein kinase by metformin improves left ventricular function and survival in heart failure. Circ Res 104 (2009) 403-411
22. Hagar J.M., Newman L.G., and Kloner R.A. Effects of amlodipine on myocardial infarction, infarct expansion, and ventricular geometry in the rat. Am Heart J 124 (1992) 571-580
23. Hale S.L., Sesti C., and Kloner R.A. Administration of erythropoietin fails to improve long-term healing or cardiac function after myocardial infarction in the rat. J Cardiovasc Pharmacol 46 (2005) 211-215
24. Weinberg E.O., Scherrer-Crosbie M., Picard M.H., et al. Rosuvastatin reduces experimental left ventricular infarct size after ischemia-reperfusion injury but not total coronary occlusion. Am J Physiol Heart Circ Physiol 288 (2005) H1802-H1809
25. Romero-Perez D., Fricovsky E., Yamazaki K., et al. Cardiac uptake of minocycline and mechanisms for in vivo cardioprotection. J Am Coll Cardiol 52 (2008) 1086-1094
26. Villarreal F.J., Griffin M., Omens J., Dillmann W., Nguyen J., and Covell J. Early short-term treatment with doxycycline modulates postinfarction left ventricular remodeling. Circulation 108 (2003) 1487-1492
27. Griffin M.O., Jinno M., Miles L.A., and Villarreal F.J. Reduction of myocardial infarct size by doxycycline: a role for plasmin inhibition. Mol Cell Biochem 270 (2005) 1-11
28. Cienfuegos-Jovellanos E., Quinones Mdel M., Muguerza B., Moulay L., Miguel M., and Aleixandre A. Antihypertensive effect of a polyphenol-rich cocoa powder industrially processed to preserve the original flavonoids of the cocoa beans. J Agric Food Chem 57 (2009) 6156-6162
29. Bolli R., Becker L., Gross G., Mentzer Jr. R., Balshaw D., and Lathrop D.A. Myocardial protection at a crossroads: the need for translation into clinical therapy. Circ Res 95 (2004) 125-134
30. Kloner R.A., and Rezkalla S.H. Cardiac protection during acute myocardial infarction: where do we stand in 2004?. J Am Coll Cardiol 44 (2004) 276-286
31. Kapoor M., Howard R., Hall I., and Appleton I. Effects of epicatechin gallate on wound healing and scar formation in a full thickness incisional wound healing model in rats. Am J Pathol 165 (2004) 299-307
32. Schroeter H., Bahia P., Spencer J.P., et al. (-)-epicatechin stimulates ERK-dependent cyclic AMP response element activity and up-regulates GluR2 in cortical neurons. J Neurochem 101 (2007) 1596-1606
33. Skyschally A., van Caster P., Boengler K., et al. Ischemic postconditioning in pigs: no causal role for RISK activation. Circ Res 104 (2009) 15-18
34. Depre C., Kim S.J., John A.S., et al. Program of cell survival underlying human and experimental hibernating myocardium. Circ Res 95 (2004) 433-440
35. Penumathsa S.V., Koneru S., Samuel S.M., et al. Strategic targets to induce neovascularization by resveratrol in hypercholesterolemic rat myocardium: role of caveolin-1, endothelial nitric oxide synthase, hemeoxygenase-1, and vascular endothelial growth factor. Free Radic Biol Med 45 (2008) 1027-1034
36. Grassi D., Necozione S., Lippi C., et al. Cocoa reduces blood pressure and insulin resistance and improves endothelium-dependent vasodilation in hypertensives. Hypertension 46 (2005) 398-405
37. van Praag H., Lucero M.J., Yeo G.W., et al. Plant-derived flavanol (-)-epicatechin enhances angiogenesis and retention of spatial memory in mice. J Neurosci 27 (2007) 5869-5878
38. Waterhouse A.L., Shirley J.R., and Donovan J.L. Antioxidants in chocolate. Lancet 348 (1996) 834
39. Hanasaki Y., Ogawa S., and Fukui S. The correlation between active oxygens scavenging and antioxidative effects of flavonoids. Free Radic Biol Med 16 (1994) 845-850
40. Aneja R., Hake P.W., Burroughs T.J., Denenberg A.G., Wong H.R., and Zingarelli B. Epigallocatechin, a green tea polyphenol, attenuates myocardial ischemia reperfusion injury in rats. Mol Med 10 (2004) 55-62
41. Selmi C., Mao T.K., Keen C.L., Schmitz H.H., and Eric Gershwin M. The anti-inflammatory properties of cocoa flavanols. J Cardiovasc Pharmacol 47 Suppl 2 (2006) S163-S171 discussion S172-6
42. Steffen Y., Schewe T., and Sies H. Myeloperoxidase-mediated LDL oxidation and endothelial cell toxicity of oxidized LDL: attenuation by (-)-epicatechin. Free Radic Res 40 (2006) 1076-1085
43. Heptinstall S., May J., Fox S., Kwik-Uribe C., and Zhao L. Cocoa flavanols and platelet and leukocyte function: recent in vitro and ex vivo studies in healthy adults. J Cardiovasc Pharmacol 47 Suppl 2 (2006) S197-S205 discussion S206-9
44. Schroeter H., Heiss C., Balzer J., et al. (-)-epicatechin mediates beneficial effects of flavanol-rich cocoa on vascular function in humans. Proc Natl Acad Sci U S A 103 (2006) 1024-1029
45. Jones S.P., and Lefer D.J. Myocardial reperfusion injury: insights gained from gene-targeted mice. News Physiol Sci 15 (2000) 303-308
46. Balzer J., Rassaf T., Heiss C., et al. Sustained benefits in vascular function through flavanol-containing cocoa in medicated diabetic patients. J Am Coll Cardiol 51 (2008) 2141-2149